Precision BioSciences (DTIL) AI Stock Analysis

• Market Cap: $88.69M
• Dividend Yield: N/A
• Average Volume (3M): 123.92K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.09
• Revenue Growth: -99.07%
• EPS Growth: -10347.56%
• Country: US
• Employees: 108
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.84
• Shares Outstanding: 13,256,751
• 10 Day Avg. Volume: 185,671
• 30 Day Avg. Volume: 123,923
• PEG Ratio: -0.03
• Price to Book (P/B): 0.46
• Price to Sales (P/S): 0.38
• P/FCF Ratio: -0.44
• Enterprise Value/Market Cap: 0.15
• Enterprise Value/Revenue: 19.48
• Enterprise Value/Gross Profit: -20.23
• Enterprise Value/Ebitda: -0.17
• 1Y Price Target: $45.00
• Price Target Upside: 780.63% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 38 Underperform
• Price Target: $5.00 ▼(-2.15% Downside)

Precision BioSciences is facing significant financial and technical challenges, with declining revenues, substantial losses, and bearish technical indicators. The negative P/E ratio further highlights the company's financial struggles. These factors contribute to a low overall stock score, reflecting high risks associated with the stock.

Positive Factors

Proprietary Technology

The ARCUS genome editing platform is a key competitive advantage, enabling precise DNA edits for innovative therapies, supporting long-term growth.

Strategic Partnerships

Strategic partnerships provide funding and development support, enhancing Precision BioSciences' ability to advance its therapeutic pipeline and sustain operations.

Improved Leverage

Improved leverage indicates better financial management, reducing risk and potentially enhancing the company's ability to invest in growth opportunities.

Negative Factors

Declining Revenues

Sharp decline in sales suggests challenges in market demand or competitive positioning, impacting long-term revenue sustainability and growth prospects.

Negative Profit Margins

Substantial losses relative to revenue indicate ongoing profitability challenges, which can hinder investment in R&D and future growth initiatives.

Negative Cash Flow

Negative cash flow highlights financial strain, limiting the company's ability to fund operations and invest in new projects without external financing.

Precision BioSciences Business Overview & Revenue Model

Company Description

Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma. The company has development and commercial license agreement with Les Laboratoires Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; and iECURE, Inc. to develop ARCUS-based gene editing therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

How the Company Makes Money

Precision BioSciences generates revenue through a combination of product sales, research collaborations, and licensing agreements. The company partners with pharmaceutical and biotechnology firms to develop therapies using its ARCUS gene editing technology, earning revenue through milestone payments and royalties from successful product developments. Additionally, Precision BioSciences may receive funding from government grants and research contracts aimed at advancing its innovative therapies. Significant partnerships with other biotech companies enhance its revenue potential by allowing shared resources and expertise in drug development.

Precision BioSciences Financial Statement Overview

Summary

Precision BioSciences is facing significant financial difficulties, characterized by declining revenues, substantial losses, and negative cash flows. While there are some improvements in leverage, the company's profitability and cash generation remain major concerns.

Income Statement

Precision BioSciences has faced significant challenges in its income statement, with a negative revenue growth rate of -44.65% in the TTM period, indicating a sharp decline in sales. The company also reported negative margins across the board, with a net profit margin of -119.77% and an EBIT margin of -87.0%, highlighting substantial losses relative to revenue. These factors suggest a struggling financial performance with limited profitability.

Balance Sheet

The balance sheet shows a mixed picture. The debt-to-equity ratio improved to 0.09 in the TTM period, indicating lower leverage compared to previous years. However, the return on equity remains deeply negative at -213.79%, reflecting ongoing losses. The equity ratio stands at 17.79%, suggesting a moderate level of equity financing relative to total assets.

Cash Flow

Cash flow analysis reveals a challenging situation with negative operating cash flow and free cash flow. The free cash flow growth rate improved by 14.43% in the TTM period, but the operating cash flow to net income ratio of -4.89 indicates that cash outflows significantly exceed net income. The free cash flow to net income ratio of 1.00 suggests that free cash flow is closely aligned with net income, albeit both are negative.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	698.00K	68.70M	48.73M	25.10M	115.53M	24.29M
Gross Profit	-672.00K	68.70M	48.73M	25.10M	115.53M	24.29M
EBITDA	-79.30M	13.53M	-32.04M	-62.79M	-20.27M	-99.19M
Net Income	-83.60M	7.17M	-61.32M	-111.64M	-30.60M	-109.01M
Balance Sheet
Total Assets	93.51M	136.39M	159.78M	238.17M	211.50M	150.16M
Cash, Cash Equivalents and Short-Term Investments	44.87M	86.31M	116.68M	189.58M	143.66M	89.80M
Total Debt	29.13M	30.05M	31.27M	24.96M	9.11M	10.52M
Total Liabilities	76.88M	80.00M	140.92M	177.74M	120.33M	105.73M
Stockholders Equity	16.63M	56.39M	18.86M	60.43M	91.17M	44.42M
Cash Flow
Free Cash Flow	-73.69M	-58.70M	-86.39M	-49.07M	-16.66M	-92.42M
Operating Cash Flow	-73.28M	-58.45M	-84.11M	-45.75M	-10.85M	-87.39M
Investing Cash Flow	-406.00K	-215.00K	5.83M	-3.32M	-5.80M	-5.03M
Financing Cash Flow	23.57M	50.45M	5.39M	94.98M	70.52M	1.33M

Precision BioSciences Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 5.11
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DTIL, the sentiment is Negative. The current price of 5.11 is below the 20-day moving average (MA) of 6.00, below the 50-day MA of 6.00, and below the 200-day MA of 5.19, indicating a bearish trend. The MACD of -0.41 indicates Positive momentum. The RSI at 38.12 is Neutral, neither overbought nor oversold. The STOCH value of 24.42 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DTIL.

Precision BioSciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CTMX	66 Neutral	$715.02M	10.09	66.76%	―	-10.26%	144.62%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BLUE	51 Neutral	―	―	―	―	127.51%	56.94%
IMA	41 Neutral	$92.14M	-1.08	-33.05%	―	-100.00%	45.48%
DTIL	38 Underperform	$88.69M	-0.80	-205.16%	―	-99.07%	-10347.56%
ACRV	36 Underperform	$74.47M	―	-50.23%	―	―	21.17%
ACET	27 Underperform	$105.79M	-0.53	-71.73%	―	―	25.89%

Precision BioSciences Corporate Events

Precision BioSciences Announces $70M Stock Offering

On November 10, 2025, Precision BioSciences, Inc. announced an underwriting agreement with Guggenheim Securities, LLC for the sale of 10,815,000 shares of common stock and accompanying warrants, expecting to raise approximately $70 million. The proceeds will be used for research and development, working capital, and other corporate purposes, with the offering’s closing anticipated on November 12, 2025, subject to customary conditions.

The most recent analyst rating on (DTIL) stock is a Buy with a $60.00 price target. To see the full list of analyst forecasts on Precision BioSciences stock, see the DTIL Stock Forecast page.

Precision BioSciences Unveils Promising ELIMINATE-B Trial Results

On November 10, 2025, Precision BioSciences announced significant findings from its ELIMINATE-B clinical trial, which evaluates the PBGENE-HBV therapy for hepatitis B. The trial demonstrated consistent antiviral activity and durable reductions in hepatitis B surface antigen across various dose levels, with no dose-limiting toxicities observed. The promising results, including direct evidence of HBV DNA editing, suggest a potential path to a cure, positioning the company favorably in the gene editing landscape and offering hope for stakeholders seeking effective hepatitis B treatments.

The most recent analyst rating on (DTIL) stock is a Hold with a $6.00 price target. To see the full list of analyst forecasts on Precision BioSciences stock, see the DTIL Stock Forecast page.

Precision BioSciences Reports Q3 2025 Financial Results

Precision BioSciences, Inc. is a clinical-stage gene editing company utilizing its proprietary ARCUS® platform to develop in vivo gene editing therapies for diseases with high unmet needs. The company recently announced its third-quarter 2025 financial results, highlighting significant progress in its gene editing pipeline, particularly with its PBGENE-HBV and PBGENE-DMD programs.

Precision BioSciences Advances with Promising Hepatitis B Gene-Editing Study

Precision BioSciences is conducting a Phase 1 study titled ‘A Phase 1, Open-Label, First-in-Human, Dose Escalation (Part 1) and Expansion (Part 2) Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of PBGENE-HBV in Participants With Chronic Hepatitis B (ELIMINATE-B).’ The study aims to assess the safety, tolerability, pharmacokinetics, and antiviral activity of PBGENE-HBV, a novel gene-editing intervention for chronic hepatitis B.

Precision BioSciences Updates Executive Employment Agreements

On August 26, 2025, Precision BioSciences amended and restated employment agreements for its key executives to retain them and reflect updated compensation terms. These agreements include provisions for termination without cause and require funding of severance and expenses in an escrow account, with interest and unused funds benefiting the company.

The most recent analyst rating on (DTIL) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on Precision BioSciences stock, see the DTIL Stock Forecast page.